GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » EV-to-EBITDA

Telomir Pharmaceuticals (Telomir Pharmaceuticals) EV-to-EBITDA : -16.81 (As of May. 17, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Telomir Pharmaceuticals's enterprise value is $183.98 Mil. Telomir Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.95 Mil. Therefore, Telomir Pharmaceuticals's EV-to-EBITDA for today is -16.81.

The historical rank and industry rank for Telomir Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

TELO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -131.63   Med: 0   Max: 3.46
Current: -16.81

During the past 3 years, the highest EV-to-EBITDA of Telomir Pharmaceuticals was 3.46. The lowest was -131.63. And the median was 0.00.

TELO's EV-to-EBITDA is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 10.28 vs TELO: -16.81

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Telomir Pharmaceuticals's stock price is $6.1819. Telomir Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.425. Therefore, Telomir Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Telomir Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Telomir Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals EV-to-EBITDA Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - - - - -

Competitive Comparison of Telomir Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Telomir Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's EV-to-EBITDA falls into.



Telomir Pharmaceuticals EV-to-EBITDA Calculation

Telomir Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=183.977/-10.945
=-16.81

Telomir Pharmaceuticals's current Enterprise Value is $183.98 Mil.
Telomir Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals  (NAS:TELO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Telomir Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.1819/-0.425
=At Loss

Telomir Pharmaceuticals's share price for today is $6.1819.
Telomir Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.425.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Telomir Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines